Expression of CD34, CD133 and CD41 on the Mk progenitor cells produced from normal bone marrow (BM) CD34+ CD133+ cells differs from that of unmanipulated BM Mk progenitor cells.

被引：0
|
作者：
Charrier, S
Boiret, N
Fouassier, M
Berger, J
John, SR
Rapatel, C
Lioret, F
Camilleri, L
Bonhomme, J
Berger, MG
机构：
[1] Fac Med, SEHM, Clermont Ferrand, France
[2] Univ Kiel, Inst Biochem, D-2300 Kiel, Germany
[3] CHU, Chirurg Cardio Vasc, Clermont Ferrand, France
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5107
引用
收藏
页码：335B / 336B
页数：2
相关论文
共 50 条
  • [21] Characterization of megakaryocytes progenitor cells differentiated from umbilical cord blood CD133+ and CD133- cells
    Goodarzi, A.
    Pour, M. Aghaeii
    Firozi, A.
    Pourfathaollah, A.
    Tabatabaeian, A.
    Vaeli, S.
    Niroomanesh, S.
    Ebtekar, M.
    Kheirandish, M.
    VOX SANGUINIS, 2006, 91 : 245 - 245
  • [22] Positive enrichment of CD133+ (AC133+) cells with the CliniMACS device: comparison to CD34
    Schumm, M
    Lang, P
    Kuci, S
    Greil, J
    Niethammer, D
    BONE MARROW TRANSPLANTATION, 2003, 31 : S211 - S211
  • [23] Transcriptional profiling reflects shared and unique characters for CD34+ and CD133+ cells
    Hemmoranta, Heidi
    Hautaniemi, Sampsa
    Niemi, Jari
    Nicorici, Daniel
    Laine, Jarmo
    Yli-Harja, Olli
    Partanen, Jukka
    Jaatinen, Taina
    STEM CELLS AND DEVELOPMENT, 2006, 15 (06) : 839 - 851
  • [24] Ex vivo expansion of canine dendritic cells from CD34+ bone marrow progenitor cells.
    Hägglund, HG
    McSweeney, PA
    Mathioudakis, G
    Bruno, B
    Georges, G
    Gass, MJ
    Moore, P
    Sale, GE
    Storb, R
    Nash, RA
    BLOOD, 1999, 94 (10) : 132A - 132A
  • [25] CD133+/CD34-subpopulation of endothelial progenitor cells: pluripotent key players in vascular disease
    Walenta, K.
    Rischar, C.
    Bohm, M.
    Friedrich, E. B.
    EUROPEAN HEART JOURNAL, 2010, 31 : 396 - 397
  • [26] Ex vivo expansion of megakaryocytes progenitor cells from umbilical cord blood CD133+ and CD133- cells
    Kheirandish, M.
    Firozi, A.
    Pourfathaollah, A.
    Tabatabaeian, A.
    Niroomanesh, S.
    Goodarzi, A.
    Vaeli, S.
    VOX SANGUINIS, 2006, 91 : 245 - 245
  • [27] Induction of apoptosis by chemotherapeutic drugs on CD34+/CD38+and CD34+/CD38-hematopoietic progenitor cells.
    Chow, KU
    Stieler, M
    Martin, H
    Rummel, MJ
    Weidmann, E
    Hoelzer, D
    Mitrou, PS
    BLOOD, 1999, 94 (10) : 154B - 154B
  • [28] Fetal bone marrow CD34(+)CD41(+) cells are enriched for multipotent hematopoietic progenitors, but not for pluripotent stem cells
    Murray, LJ
    Mandich, D
    Bruno, E
    DiGiusto, RK
    Fu, WC
    Sutherland, DR
    Hoffman, R
    Tsukamoto, A
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (02) : 236 - 245
  • [29] ARRAY BASED ANALYSIS OF MIRNA AND MRNA EXPRESSION CHARACTERIZES EARLY DIFFERENTIATION PATHWAYS OF CD133+ AND CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS
    Bissels, U.
    Wild, S.
    Tomiuk, S.
    Hafner, M.
    Scheel, H.
    Mihailovic, A.
    Choi, Y.
    Tuschl, T.
    Bosio, A.
    EXPERIMENTAL HEMATOLOGY, 2011, 39 (08) : S57 - S58
  • [30] CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors
    Shmelkov, Sergey V.
    Butler, Jason M.
    Hooper, Andrea T.
    Hormigo, Adilia
    Kushner, Jared
    Milde, Till
    St. Clair, Ryan
    Baljevic, Muhamed
    White, Ian
    Jin, David K.
    Chadburn, Amy
    Murphy, Andrew J.
    Valenzuela, David M.
    Gale, Nicholas W.
    Thurston, Gavin
    Yancopoulos, George D.
    D'Angelica, Michael
    Kemeny, Nancy
    Lyden, David
    Rafii, Shahin
    JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (06): : 2111 - 2120
12345